Zacks Small Cap Research – MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers… – Technologist
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Capital Efficient Model Propels Large Late Stage Pipeline MediciNova, Inc. (NASDAQ:MNOV) is developing MN-166 (ibudilast) for a wide range of neurological disorders and MN-001 (tipelukast) for fibrotic and other diseases. An overview of the company’s pipeline is below. MediciNova maintains a capital-efficient … Read more